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Retroviral vectors derived from murine leukemia virus (MLV) have been pseudotyped with a variant of the envelope
glycoprotein (Env) of nonpathogenic simian immunodeficiency virus from African green monkeys (SIVagm) to result in
[MLV(SIVagm-wt)] vector particles. The variant env gene encodes a full-length surface envelope glycoprotein (SU) and a
C-terminally truncated transmembrane protein (TM). To change the coreceptor usage of this vector from CCR5 to CXCR4,
which is predominant on human CD4-positive lymphocytes, the putative V3-loop of SIVagm SU was replaced by that of the
T cell tropic HIV-1 variant BH10. The resulting [MLV(SIVagm-X4)] vectors were shown to specifically transduce CD4/CXCR4-
positive cell lines, demonstrating the equivalent function in cell entry and choice of coreceptor usage of the V3-loops of
SIVagm and HIV-1. These modified vectors were able to transduce primary human lymphocytes and were resistant to
neutralization by sera from HIV-1-infected individuals. The [MLV(SIVagm-X4)] pseudotype vector generated is thus aINTRODUCTION
CD4 T cells are promising targets for gene transfer
approaches aiming at the prevention of human immuno-
deficiency virus (HIV) infection or the treatment of AIDS.
To develop CD4-specific retroviral vectors, Moloney mu-
rine leukemia virus (MLV) has been pseudotyped with
variant envelope glycoprotein (Env) of a variety of lenti-
viruses including HIV-1 (Schnierle et al., 1997; Mammano
et al., 1997; Lodge et al., 1998), HIV-2 (Ho¨hne et al., 1999),
the simian immunodeficiency virus from African green
monkeys (SIVagm) (Stitz et al., 2000), and SIVmac from
rhesus macaques (Indraccolo et al., 1998). Truncation of
the C-terminal domain of the transmembrane envelope
glycoprotein (TM) of HIV-1, HIV-2, and SIVagm was nec-
essary to allow formation of infectious pseudotype vector
particles. In contrast to [MLV(HIV-1)] vectors, [MLV-
(SIVagm)] vectors were shown to be resistant to neutral-
ization by a variety of sera from HIV-1 seropositives (Stitz
et al., 2000). Therefore, [MLV(SIVagm)] vectors may be
superior to [MLV(HIV-1)] vectors for in vivo gene therapy
of HIV-1-infected patients.
Infection of cells by HIV and SIV requires a functional
interaction of the surface envelope glycoprotein (SU)
with at least two cell-surface molecules. These are the
primary receptor CD4 and a coreceptor. All coreceptors
identified until today belong to the chemokine receptor
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dressed at Department of Medical Biotechnology, Paul-Ehrlich-Institut,205family of seven-membrane spanning receptors (Choe et
al., 1996; Deng et al., 1996). The major HIV-1 coreceptors
are CCR5 and CXCR4, while most SIV isolates use CCR5
or alternative coreceptors such as Bob or Bonzo (Deng et
al., 1997). However, depending on the donor, 50–80%
of human CD4-positive T cells are CXCR4-positive,
whereas only 5–15% express CCR5 (Ostrowski et al.,
1998; Vassiliadou et al., 1999; Blanco et al., 1999; I.
Schmitt and K. Cichutek, unpublished data). The pattern
and regulation of Bonzo expression on the surface of
CD4-positive cells closely parallel that of CCR5 and are
inversely correlated with CXCR4 expression (Unutmaz et
al., 2000). Thus, we attempted to generate [MLV(SIVagm)]
vector particles able to use the coreceptor CXCR4 for cell
entry and would therefore be suitable for efficient trans-
duction of the majority of the target T cells of HIV-1
replication, i.e., human CD4/CXCR4-positive T cells.
The cell tropism of HIV-1 is mainly determined by the
V3-loop region of SU (Hwang et al., 1991; Shioda et al.,
1992; Choe et al., 1996; Speck et al., 1997). Exchange of
the V3-loops between CCR5-tropic and CXCR4-tropic
HIV-1 strains were shown to be sufficient for a switch of
the cell tropism of the resulting viruses (Sato et al., 1999;
LaBranche et al., 1999). Analysis of HIV-1 Env chimeras
containing the V3-loop of an SIVmac/HIV-1 hybrid virus
(Hoffman et al., 1998) indicated that the V3-loop is the
major determinant of CXCR4 specificity, whereas the V1-
and V2-loops of Env are more important for binding to
coreceptors other than CXCR4. It is well known that
basic amino acid residues in the V3-loop of HIV-1 allowpromising candidate vector, e.g., for in vivo gene therapy o
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enable the use of CXCR4 (Meister et al., 2001), and also
substitution of the complete V3-loop of the SIVmac SU
against that of HIV-1 did not allow the generation of
replication-competent SIVmac variants with alternative
coreceptor usage (Kirchhoff et al., 1994a; Mamounas et
al., 1995).
Although the V3-loop of SIVagm has not been suffi-
ciently analyzed, we speculated that it would play a
similar role in coreceptor binding as that of HIV-1. To
switch the coreceptor usage of [MLV(SIVagm-wt)] vec-
tors containing the truncated SIVagm Env variant encom-
passing the wild-type SU from CCR5 to CXCR4, we iden-
tified a putative V3-loop region in the SIVagm SU. This
region was replaced by the V3-loop of the T cell tropic
HIV-1 variant BH10. We show here that the resulting [MLV
(SIVagm-X4)] pseudotype vector particles were able to
transduce CD4/CXCR4-positive cells, whereas cell entry
was no more mediated by CCR5 or Bonzo. This demon-
strates the functional equivalency of the V3-loop of
SIVagm with that of HIV-1 in terms of cell entry and
coreceptor recognition. [MLV(SIVagm-X4)] vectors were
able to transduce primary human lymphocytes and were
still resistant to neutralization by sera from HIV-1-sero-
positives, thus providing an important advantage over
[MLV(HIV-1)] vectors for future in vivo gene therapy ap-
plications.
RESULTS
Substitution of the SIVagm V3-loop in the surface
envelope glycoprotein
By comparing the env gene sequence of a molecular
clone of SIVagm3 (SIVagm3mc) (Baier et al., 1989) with
that of the CD4/CXCR4-tropic HIV-1 strain BH10 (Wong-
Staal et al., 1985) and the CD4/CCR5-tropic HIV-1 strain
MBK (Cichutek et al., 1992), a 34 amino acid stretch in the
SU of SIVagm3mc was identified as the HIV-1 V3-loop
homolog due to the presence of cystein residues at the
5 and 3 ends as well as other identical amino acids in
similar positions (Fig. 1B). Within this region, the amino
acid sequence homology between HIV-1 BH10 and
SIVagm3mc was 33%.
To switch the coreceptor usage of SIVagm, the V3-loop
encoding region was substituted by that of the CD4/CXCR4-
tropic HIV-1 variant BH10. Using fusion PCR, the V3-loop-
encoding region of plasmid pRep10env, which encodes a
C-terminally truncated env gene and the entire rev gene of
SIVagm (Fig. 1A), was replaced by the V3-loop of the T cell
tropic HIV-1 variant BH10 (Fig. 2). The overall structure of
the resulting chimeric env expression construct designated
Rep10env-X4 was verified by sequence analysis (data not
shown).
To prove functional expression of the V3-loop-modified
SIVagm Env in human 293T cells, fusion activity was
investigated. For this purpose, 293T cells were trans-
fected with plasmid pRep10env or pRep10env-X4, re-
spectively, and cocultivated with the CD4-positive human
T cell line Molt4/8. Molt4/8 cells express high levels of
CXCR4 and only a low level of CCR5 (Dejucq et al., 1999).
After 2 days, large syncytia were detected by light mi-
croscopy in cocultures of 293T cells expressing
SIVagm-wt Env or SIVagm-X4 Env, but not in untrans-
fected cultures used as controls (Fig. 3). Following in situ
immunoperoxidase assay (IPA) using serum from an
SIVagm3-positive macaque, the syncytia were stained,
indicating that their formation was indeed induced by
expression of the respective fusion-competent env gene
products (Fig. 3). These data indicated (i) expression of
env gene products on the cell surface, (ii) binding of env
gene products to receptors on the surface of Molt4/8
cells, and (iii) fusion capacity of both variant envelope
glycoproteins. Obviously, due to the known high sensi-
tivity of this syncytium assay, the low levels of CCR5 on
Molt4/8 cells were sufficient for syncytium induction by
FIG. 1. SIVagm envelope used for generation of pseudotype vectors.(A) Schematic representation of SIVagm env expression construct pRep10env
encoding also rev sequences as well as a hygromycin B expression cassette (not shown). The C-tail of the transmembrane protein (TM) was truncated
to enable pseudotyping of MoMLV capsids. pRep10env encodes the full-length wild-type SIVagm3mc SU (Baier et al., 1989; Stitz et al., 2000). TMR:
transmembrane region. (B) Comparison of the V3-loop amino acid sequences of SIVagm3mc, T cell-tropic HIV-1 strain BH10 (Wong-Staal et al., 1985),
and macrophage-tropic HIV-1 strain MBK (Cichutek et al., 1992).
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the SIVagm-wt Env. It was concluded that SIVagm-X4 Env
was fully functional.
Transient generation of infectious [MLV(SIVagm-X4)]
pseudotype vector particles and construction of
stable packaging cell lines
To generate retroviral pseudotype vector particles, tri-
ple cotransfections of 293T cells were performed using
the packaging signal psi-negative MoMLV gag/pol en-
coding plasmid pHIT60, the psi-positive MLV-derived ret-
roviral transfer vector MFG-nlsLacZ containing the lacZ
marker gene, and either plasmid pRep10env or
pRep10env-X4, the latter two encoding the psi-negative
SIVagm Env variants (Fig. 1A). Two days after transfec-
tion, supernatants were filtered and used for the trans-
duction of GHOST cell lines (Cecilia et al., 1998), which
express either human CD4 alone (GHOST-parental) or
CD4 in conjunction with one of the HIV-1 coreceptors
CCR5, CXCR4, or Bonzo. Two days posttransduction the
cells were stained to detect transduced, -galactosi-
FIG. 2. Replacing the V3-loop of SIVagm env by the V3-loop of HIV-1 strain BH10 env using fusion PCR. Schematic representation of PCR and cloning
strategy. The env fragments were amplified by PCR 1 to 3 using oligonucleotide primers A–F as indicated. C and D are chimeric primers containing
sequences of SIVagm and HIV-1. Amplified fragments were mixed and used as templates for fusion PCR using primes A and F. The resulting
SIVagm-X4 env fragment containing the V3-loop of HIV-1 BH10 was ligated into pRep10env via restriction sites BsrGI and BstZ17I.
FIG. 3. Fusogenicity of SIVagm Env variants. Cocultivation of 293T cells transfected with the SIVagm Env variant indicated or mock-transfected with
cells of the human T cell line Molt4/8. IPA staining of env expressing cells was performed using SIVagm-positive monkey serum after 2 days of
cocultivation.
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dase-expressing cells. Using [MLV(SIVagm-wt)] vectors,
efficient transduction was obtained in GHOST-CCR5
cells [corresponding to 1.3  104 infectious units per ml
(i.u./ml)] and in GHOST-Bonzo cells (5.8  103 i.u./ml).
[MLV(SIVagm-X4)] vectors were able to transduce
GHOST-CXCR4 cells (3.9  103 i.u./ml). All other GHOST
cells including GHOST-parental cells revealed only low-
level transduction which was most likely due to a low
level of endogenous expression of CXCR4 and Bonzo
(Edinger et al., 1998). This demonstrated that the tropism
of the [MLV(SIVagm-X4)] vector was changed from CD4/
CCR5 and CD4/Bonzo to CD4/CXCR4 by the V3-loop
exchange.
For continuous production of supernatants containing
high titers of [MLV(SIVagm-wt)] and [MLV(SIVagm-X4)]
pseudotype vectors, stable packaging cell lines were
generated. Therefore, TELCeB6 cells (Cosset et al.,
1995), which contain a psi-positive retroviral transfer vec-
tor and a psi-negative MLV gag/pol expression plasmid,
were transfected either with plasmid pRep10env or with
pRep10env-X4, both encoding a hygromycin B resis-
tance gene in addition to the SIVagm Env variant. After
hygromycin B selection of the transfected cells and
screening of more than 200 resistant colonies per cell
line for vector production, we obtained cell clone wt.6
producing [MLV(SIVagm-wt)] vector particles with a titer
of 7.6  105 i.u./ml as determined in GHOST-CCR5 cells,
and cell clone X4.3 producing 6.0  103 i.u./ml of [MLV-
(SIVagm-X4)] vector particles as determined in GHOST-
CXCR4 cells. Using ultracentrifugation, 100-fold concen-
tration of the vector stocks was routinely achieved.
Detection of truncated SIVagm Env in supernatant of
packaging cells
To analyze the expression of the SIVagm Env variants,
20 ml culture supernatant from the stable packaging
cells were pelleted by ultracentrifugation through su-
crose cushions. Vector particles obtained in the pellets
were analyzed by Western blotting (Fig. 4). Purified pellet
from supernatants of nontransfected TELCeB6 cells was
used as a negative control. Following staining of Western
blots using serum from an SIVagm3-infected macaque, a
characteristic band corresponding to gp140-SU of
SIVagm (Kraus et al., 1989) was detected in supernatants
obtained from [MLV(SIVagm-wt)] and [MLV(SIVagm-X4)]
vector-producing cells, but not in the negative control
pellet. However, the amount of gp140-SU detected in
supernatants of [MLV(SIVagm-X4)]-producing cells was
significantly lower than that detected in supernatants of
[MLV(SIVagm-wt)]-producing cells. A band correspond-
ing to a molecular weight of about 29 kDa was detected
in comparable amounts in both vector pellets, but not in
the negative control. The apparent molecular weight of
29 kDa corresponded to the theoretical molecular weight
of the truncated SIVagm TM protein considering the
truncation of the wild-type gp45-TM by 135 C-terminal
amino acids. Since the levels of the gp29-TM10 pro-
teins detected in supernatants from [MLV(SIVagm-wt)]-
and [MLV(SIVagm-X4)]-producing cells were equivalent,
the difference in the amounts of gp140-SU is most prob-
ably due to increased shedding of the gp140-SU from
[MLV(SIVagm-X4)]-producing cells or respective vectors.
Although incorporation of the Env proteins into the re-
spective vector particles can be assumed, it is not un-
equivocally proven by the Western blot data, since su-
pernatants from TE671 cells, transfected either with plas-
mid pRep10env or with pRep10env-X4 and thus
expressing only Env proteins but no other vector com-
ponents, revealed a similar Env protein pattern (data not
shown), thus indicating copelleting of nonincorporated
Env. Additional bands were obviously unspecific be-
cause they were also detected in the negative control
pellet. To detect MLV proteins, the blot was intensively
washed and relabeled using a polyclonal serum able to
detect p30-Gag of MLV. Bands of the corresponding
molecular weight were stained in the supernatants from
SIVagm env-transfected and mock-transfected TELCeB6
cells (Fig. 4), providing evidence for the release of vector
particles containing MLV capsids.
Coreceptor usage of [MLV(SIVagm-X4)] vectors
To investigate the usage of additional coreceptors
besides CCR5, Bonzo, and CXCR4 by the [MLV(SIVagm)]
vectors generated, we transduced a panel of 10 GHOST
cell lines, each expressing either human CD4 alone or
CD4 in conjunction with one of several chemokine re-
ceptors known to function as coreceptors for cell entry of
FIG. 4. Detection of SIVagm envelope protein in packaging cell
supernatants. Particles were concentrated and purified from packaging
cell supernatants by centrifugation through sucrose cushions and an-
alyzed on Western blot using polyclonal anti MLVp30gag serum (left) or
SIVagm-positive monkey serum (right). SIVagm-wt: supernatant from
[MLV(SIVagm-wt)] producing cell line 1wt.6. SIVagm-X4: supernatant
from [MLV(SIVagm-X4)] producing cell line 1X4.3. Mock: supernatant
from TELCeB6 cells. gp140-SU: SIVagm Env surface protein. gp29-
TM10: SIVagm Env transmembrane protein, C-terminally truncated.
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HIV and SIV. Cultures of all GHOST cell lines were
incubated with various dilutions of [MLV(SIVagm-wt)] or
[MLV(SIVagm-X4)] vector-containing supernatants har-
vested from the stable packaging cell lines. As controls,
[MLV(HIV-1)] vectors which were generated either from
packaging cell line K52SR20 harboring the CXCR4-tropic
env of HIV-1 BH10 (Stitz et al., 1998) or from packaging
cell line MBK15 harboring the CCR5-tropic env gene of
HIV-1 BH10 modified by inserting the V3-loop of MBK (I.
Schmitt and K. Cichutek, unpublished data) were used.
These vectors, here designated as [MLV(HIV-X4)] and
[MLV(HIV-R5)], respectively, were generated with titers of
7.0  105 and 1.0  106 i.u./ml, respectively, tested on
GHOST-CXCR4 or GHOST-CCR5 cells. Two days after
transduction, the percentage of transduced cells was
determined by X-Gal staining (Fig. 5).
Using [MLV(SIVagm-wt)] vectors, cells expressing CD4
and CCR5 were transduced most efficiently (Fig. 5A).
GHOST cells expressing CD4 and Bonzo were also
transduced, albeit at a lower percentage of about 60%
relative to the CD4/CCR5 cells. A background transduc-
tion below 3% was observed with the other GHOST cell
lines and was hypothesized to be due to low endoge-
nous expression of Bonzo in GHOST cells (Edinger et al.,
1998). [MLV(HIV-R5)] vectors used CCR5 as a coreceptor
but were not able to use any further coreceptor.
[MLV(SIVagm-X4)] vector particles revealed an essen-
tially identical transduction pattern as [MLV(HIV-X4)] vec-
tors encompassing the same V3-loop derived from HIV-1
BH10 Env (Fig. 5B). Aside from efficient transduction of
GHOST-CXCR4 cells, a pattern of background transduc-
tion of other GHOST cells mediated by endogenous
CXCR4 expression (Edinger et al., 1998) was also iden-
tical for [MLV(SIVagm-X4)] and [MLV(HIV-X4)] vectors.
Thus, the coreceptor switch from CCR5/Bonzo to CXCR4
due to exchange of the V3-loop observed when using
transiently generated [MLV(SIVagm)] vectors was con-
firmed with supernatant from stable cell lines.
To further prove the exclusive usage of the CXCR4
coreceptor by [MLV(SIVagm-X4)] vector, inhibition exper-
iments were carried out using the stromal-derived factor
1 (SDF-1), the natural ligand of CXCR4 (Oberlin et al.,
1996). In the presence of various amounts of SDF-1,
GHOST-CCR5 or GHOST-CXCR4 cells were transduced
at an m.o.i. of 0.5 with [MLV(SIVagm-wt)] or [MLV-
(SIVagm-X4)] vectors, respectively. Two days after trans-
duction, X-Gal staining revealed that the transduction
efficiency of the [MLV(SIVagm-X4)] vector was reduced
by SDF-1 in a dose-dependent manner down to 4.5% at
an SDF-1 concentration of 4 g/ml, whereas the trans-
duction efficiency of the [MLV(SIVagm-wt)] vector was
not impaired (Fig. 6). These data demonstrate unequiv-
ocally the coreceptor switch of the [MLV(SIVagm)]
pseudotype vector after V3-loop exchange.
[MLV(SIVagm-X4)] pseudotype vectors are resistant
to neutralization by sera from HIV-1-infected
individuals
In contrast to [MLV(HIV-X4)] vectors, [MLV(SIVagm-wt)]
vectors have been shown to be relatively resistant to
neutralization by anti-HIV-1 antibodies (Stitz et al., 2000).
By insertion of the HIV-1 V3-loop, this resistance to neu-
tralization may have been decreased, as many of the
neutralizing antibodies against HIV-1 have been shown
to be directed against the V3-loop. Therefore, neutraliza-
FIG. 5. Coreceptor usage of [MLV(HIV-1)] and [MLV(SIVagm)] pseudotype vectors. Relative transduction efficiencies on GHOST cells expressing
CD4 and one coreceptor as indicated. Results shown represent the average of three independent experiments, and bars represent standard
deviations. Transduction efficiencies on GHOST-CXCR4 or GHOST-CCR5 cells in each experiment, respectively, were set as 100%. (A) Transduction
efficiencies of CCR5-tropic vectors. (B) Transduction efficiencies of CXCR4-tropic vectors.
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tion experiments were performed with [MLV(SIVagm-X4)]
vector particles using sera from four asymptomatic HIV-
1-infected donors. These sera had previously been
shown to neutralize various T cell line adapted strains
and primary isolates of HIV-1 (S. Norley and R. Kurth,
unpublished data). [MLV(SIVagm-wt)], [MLV(SIVagm-X4)],
[MLV(HIV-X4)], and [MLV(MLV-A)] vectors, respectively,
were incubated for 1 h at 37°C with sera and were then
used for the transduction of the respective target GHOST
cell line. The resulting titer was determined by X-Gal
staining 2 days later (Fig. 7). For comparison, the mean
titer obtained after incubation with control sera from four
healthy donors was set to 100%. Compared to these
controls, the transduction titers of [MLV(HIV-X4)] vectors
were reduced approximately 60% using the HIV-1-posi-
tive sera. In contrast, titers of [MLV(SIVagm-wt)] and
[MLV(SIVagm-X4)] were approximately 6 to 19% reduced,
which was in a similar range as observed for [MLV(MLV-
A)] vector (22%). Thus, V3-loop substitution in [MLV-
(SIVagm)] vector particles did not affect the absence from
neutralization by sera from HIV-1 seropositives.
Transduction of primary human lymphocytes using
[MLV(SIVagm-X4)] vectors
To test the ability of [MLV(SIVagm-X4)] vectors to trans-
duce primary human peripheral blood lymphocytes
(PBLs), vectors transferring the egfp gene were gener-
ated by transient triple transfection of 293T cells with
MoMLV Gag/Pol expression plasmid pHIT60, the pack-
aging vector plasmid pMgEGFP-LNGFR, and the
SIVagm-X4 env expression construct Rep10env-X4.
[MLV(MLV-A)] vectors were generated similarly using
MLV-A env expression construct ALF-MLV-A. PBL of
three human donors were purified by Ficoll gradient
centrifugation and stimulated for 3 days with immobilized
monoclonal antibodies directed against CD3 and CD28
in the presence of IL-2. 5  104 PBL were transduced on
fibronectin-coated plates with 1 ml of supernatant from
transiently transfected 293T. More than 95% of these
cells expressed CD3 at the time of transduction, as
assessed by anti-CD3 antibody labeling and FACS anal-
ysis (not shown). Three cycles of transduction were per-
formed on consecutive days containing the total amount
of 5  104 i.u. of [MLV(SIVagm-X4)] or 1.5  105 i.u. of
[MLV(MLV-A)] vectors estimated on Molt4/8 cells. Three
days after the last transduction, PBLs were analyzed by
FACS for expression of EGFP and CD4 (Fig. 8, Table 1).
Considering the low m.o.i. that had to be used due the
low titer of the transiently generated egfp-transferring
vectors, [MLV(SIVagm-X4)] vectors were thus shown to
enable efficient gene transfer into the CD4-positive frac-
tion of primary PBLs. Transduction levels varied between
the three donors from 8.3 to 22.2%. As expected, CD4-
negative cells were not transduced, showing the recep-
tor specificity of the modified vector. In contrast, the
[MLV(MLV-A)] vector transduced both CD4-positive and
CD4-negative cells with nearly equal efficiency for each
donor.
Determining the coreceptor expression pattern of the
transduced cultures revealed strong fluctuations in the
numbers of CCR5- or CXCR4-expressing cells after trans-
duction (data not shown). This was in accordance with a
previous publication showing that, in contrast to CD4, the
expression of CXCR4 and CCR5 in primary cells is not
constitutive but strongly regulated and varies largely
after stimulation, e.g., with IL-2 (Bleul et al., 1997). It was
therefore not possible to analyze the coreceptor usage of
the vectors in primary cells.
FIG. 7. Absence of neutralization of [MLV(SIVagm)] vectors by sera
from HIV-1-infected donors. Relative transduction efficiencies of the
vectors indicated on suitable target cells after incubation with human
sera. The mean titer observed after incubation with sera from four
healthy donors was set at 100%. Transduction efficiencies indicated
represent the means of three independent experiments using sera from
four different HIV-1-infected donors. Bars represent standard devia-
tions. The difference between the four groups was statistically signifi-
cant (P  0.001, ANOVA). Pairwise comparisons also revealed a sta-
tistically significant difference between [MLV(HIV-X4)] and [MLV-
(SIVagm-X4)] (P  0.001), as well as between [MLV(HIV-X4)] and
[MLV(SIVagm-wt)] (P  0.001).
FIG. 6. Inhibition of transduction of [MLV(SIVagm-X4)] vector by
SDF-1. Relative transduction efficiencies of the vectors on GHOST-
CCR5 or GHOST-CXCR4 cells in the presence of various concentrations
of SDF-1 are shown. Results represent the average of two independent
experiments. Bars represent standard deviations.
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DISCUSSION
To generate retroviral vectors for the specific trans-
duction of CD4-positive T cells in future gene therapy
approaches of AIDS, MLV has been successfully
pseudotyped with C-terminally truncated Env variants of
HIV and SIV (Schnierle et al., 1997; Indraccolo et al., 1998;
Lodge et al., 1998; Ho¨hne et al., 1999; Stitz et al., 2000).
The env variants encoded a full-length SU and a
C-terminally truncated TM. In contrast to [MLV(HIV-1)]
vectors, [MLV(SIVagm)] vectors are resistant to neutral-
ization by sera from HIV-1-seropositives and may there-
fore be suitable for in vivo gene therapy strategies in
HIV-1-positive patients (Stitz et al., 1998). However, only
the small CCR5- or Bonzo-positive fraction of human
CD4-positive T-lymphocytes can be transduced by [MLV-
(SIVagm-wt)] vectors encoding the full-length SU of wt
SIVagm3mc (Baier et al., 1989). Therefore, we intended to
expand the tropism of [MLV(SIVagm-wt)] vectors to the
majority of CD4-positive cells expressing CXCR4 by mod-
ifying the SIVagm SU.
In HIV-1, the V3-loop of SU was identified as the major
determinant of CXCR4- and CCR5-coreceptor specificity
(Hwang et al., 1991; Shioda et al., 1992; Choe et al., 1996;
Speck et al., 1997), whereas other Env sequences, in
conjunction with V3, seem to be more important for SU
binding to other coreceptors (Ross and Cullen, 1998;
Hoffman et al., 1998). In contrast, the determinants of the
coreceptor tropism of SIV Env are not known in detail.
Major differences of V3-loops of SIV to those of HIV-1
have been reported. V3-loops of SIV isolates are highly
conserved (Overbaugh et al., 1991; Owen et al., 2000),
and neutralizing antibodies directed against the respec-
tive V3-loops are only poorly induced (Javaherian et al.,
1992, 1994; Glamann et al., 1998). This may indicate a
subtly different function of SIV compared to HIV-1 V3-
loops. Moreover, from a comparative sequence analysis
of V3-loops of several SIV strains including SIVagm re-
vealing a variety of different coreceptor usages, as well
as from inconsistent inhibition experiments using vari-
ous blocking compounds, it has been concluded that
coreceptor usage of SIV isolates is also dependent on
Env sequences other than the V3-loop (Owen et al.,
2000). A consensus motif that predicts coreceptor usage
has been suggested up to now exclusively for HIV-1
strains but not for HIV-2 or SIV (Xiao et al., 1998; Owen et
al., 1998). On the other hand, there are some hints that
V3-loops of SIV may play a similar role for coreceptor
recognition as the respective V3-loop of HIV-1 (Kirchhoff
et al., 1994b). Monoclonal antibodies against the V3-loop
of SIVmac blocked CCR5 binding (Edinger et al., 2000),
and exchange of single amino acids within the V3-loop
influenced the usage of coreceptors other than CCR5
(Pohlmann et al., 1999). We therefore hypothesized that
the coreceptor usage of SIVagm may also be influenced
by V3-loop exchange. With a view to future gene therapy
applications we aimed at expanding the tropism of [MLV-
(SIVagm)] vector particles. Thus, a 34 amino acid ho-
molog of the HIV-1 V3-loop localized by sequence com-
parison in the SIVagm3mc SU was replaced by the 36
amino acid V3-loop of the CXCR4-tropic HIV-1 strain
BH10. The SIVagm-X4 Env protein was shown to retain
its fusion capacity and could be used to generate
pseudotype vectors suitable for transduction of CD4/
CXCR4-positive target cells, proving incorporation of the
TABLE 1
Transduction Efficiencies of [MLV(SIVagm-X4)] and [MLV(MLV-A)]
Pseudotype Vectors in Primary Human CD4-Positive or CD4-Negative
Lymphocytes from Three Donors
[MLV(SIVagm-X4)] [MLV(MLV-A)]
CD4 CD4 CD4 CD4
Donor I 22.2% 0.7% 14.2% 18.4%
Donor II 8.3% 0.1% 25.7% 25.7%
Donor III 14.6% 0.3% 17.3% 21.8%
FIG. 8. Transduction of primary human peripheral blood lymphocytes
by [MLV(SIVagm-X4)] vectors. FACS analysis of PBL1 from three human
donors for expression of CD4 and EGFP 3 days after transduction with
the vectors indicated. Transduction efficiencies derived from this figure
are given in Table 1.
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respective Env protein into infectious vector particles.
However, the titer of the [MLV(SIVagm-X4)] vector was
lower than that of the [MLV(SIVagm-wt)] vector. The rea-
son for this is unknown. It may be caused by decreased
particle production or by a given lower infectivity of the
[MLV(SIVagm-X4)] particles, the latter due to a lower
level of SIVagm-X4 Env proteins per particle or to a lower
affinity of the SIVagm-X4 Env to the cellular receptors. As
determined by Western blot analysis, the SIVagm-wt and
SIVagm-X4-derived gp29-TM10 proteins were present
in comparable amounts in the supernatants of respective
packaging cells. Thus, it can be concluded that expres-
sion or intracellular transport of the SIVagm-X4 Env pro-
tein was normal. Differences in the amount of the
gp140-SU proteins detected by Western blot analysis are
probably due to different extents of SU shedding.
Transduction studies of [MLV(SIVagm)] vectors on the
GHOST cell panel including inhibition studies using
SDF-1, the natural ligand of CXCR4, unequivocally proved
a switch in coreceptor usage from CCR5/Bonzo to
CXCR4 due to the V3-loop exchange. This shows that the
SIVagm Env V3-loop is a major determinant of SIV core-
ceptor usage, although the amino acid homology be-
tween the sequences exchanged is only 33%. Until now,
V3-loops have only been exchanged successfully be-
tween different strains of HIV-1 (Sato et al., 1999; La-
Branche et al., 1999; I. Schmitt and K. Cichutek, unpub-
lished data) or between HIV-1 and HIV-2 (Mamounas et
al., 1995). Efforts to switch coreceptor usage by V3-loop
substitutions between SIVmac and HIV-1 have failed until
now (Kirchhoff et al., 1994a; Meister et al., 2001; Mamou-
nas et al., 1995). Since in all cases the V3-loop regions
were exchanged, it seems that the SIVagm Env proteins
are more flexible than those of SIVmac.
The results described here demonstrate that a func-
tional exchange of the V3-loop is possible between
SIVagm and HIV-1. Moreover, the SIVagm SU was redi-
rected toward CXCR4, although all but one (Schols and
De Clercq, 1997) primary SIV strains isolated until re-
cently revealed tropism for CCR5-positive cells and can-
not use CXCR4 as a coreceptor (Chen et al., 1997; Kirch-
hoff et al., 1994b; Marx and Chen, 1998). Recently, some
SIV isolates have been described which can also use
CXCR4 to a low extent in addition to their major core-
ceptor CCR5 (Owen et al., 2000). Remarkably, the modi-
fied CXCR4-tropic SIVagm Env described here is no more
able to use CCR5. Ongoing studies in our lab using
replication-competent CXCR4-tropic SIVagm, modified by
V3-loop exchange in an analogous way, will enlighten
the significance of coreceptor usage for pathogenesis in
monkeys (R. Ko¨nig and K. Cichutek, unpublished data).
Sera from HIV-1-positive donors are known to contain
high levels of neutralizing antibodies against the V3-loop
(Sattentau and Moore, 1995; Burton, 1997). In contrast to
[MLV(SIVagm-wt)], the [MLV(SIVagm-X4)] vector contains
the V3-loop of an HIV-1 strain, which accordingly may
enable neutralization by HIV-1-positive human sera.
However, neutralization assays revealed a significantly
lower neutralization activity against [MLV(SIVagm-X4)]
vectors compared to [MLV(HIV-1)] when sera from four
human HIV-1-positive donors were used. Since both vec-
tors do possess the same V3-loop, the difference in
neutralization sensitivity may be due to antigens pre-
sented in other Env regions than V3, or to different
conformations of the same V3-loop in different contexts.
In summary, it was shown that by exchange of the
V3-loop in SU of a CCR5/Bonzo-tropic [MLV(SIVagm)]
vector by that of a CXCR4-tropic HIV-1 strain the core-
ceptor usage was changed accordingly. This result
proves an essential function of V3 for coreceptor binding
for simian lentiviruses as well as for HIV-1, either by
direct binding or in conjunction with other Env regions.
Since the new [MLV(SIVagm-X4)] vectors retained resis-
tance against neutralization by HIV-1 sera and were able
to transduce primary human CD4-positive lymphocytes,
they may be useful tools for the delivery of therapeutic
genes during the treatment of AIDS, in particular for in
vivo applications. Although various protocols for trans-
duction of T-lymphocytes ex vivo have been used in gene
therapy, in vivo applications theoretically offer several
advantages, e.g., the avoidance of a contamination risk
or the risk of clonal selection during cultivation of lym-
phocytes ex vivo. However, although stable packaging
cell lines were generated for the production of [MLV-
(SIVagm-X4)] vectors, the titers of 6 103 i.u./ml obtained
here are too low to readily allow in vivo applications.
Accordingly, further optimization of vector titers and
large-scale production will be needed.
MATERIALS AND METHODS
Plasmids
MoMLV gag/pol expression construct pHIT60 (So-
neoka et al., 1995) was obtained from A. Kingsman,
Oxford, U.K. HIV-1 Env expression construct pTr712 (Wilk
et al., 1992), harboring a C-terminally truncated variant of
the T cell tropic HIV-1 Env strain BH10 (Wong-Staal et al.,
1985), was a gift from V. Bosch (Heidelberg, Germany).
pRep10env codes for a C-terminally truncated form of
SIVagm3mc env (Stitz et al., 2000) and also contains a
hygromycin B selection cassette (Fig. 1A). pMFG-nlsLacZ
(Ferry et al., 1991) encoding a retroviral transfer vector
derived from MLV encompassing the reporter gene lacZ
was a gift of S. Russel, Cambridge, U.K. The retroviral
transfer vector MgEGFP-LNGFR codes for EGFP (Clon-
tech, Palo Alto, CA) and a truncated low-affinity human
nerve growth factor receptor (LNGFR) which are ex-
pressed under the control of a murine stem cell virus
(MSCV) LTR. Amphotropic MLV Env (MLV-A) expression
construct pALF-MLV-A was generated according to Cos-
set et al. (1995), by replacing the PERV Env of pFBMOALF
(Takeuchi et al., 1998) by a PCR fragment containing the
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open reading frame of the amphotropic MLV env 4070A
gene framed by XbaI-ClaI restriction sites.
Exchange of the V3-loop of SIVagm env by fusion
PCR
pRep10env-X4 was generated by precise replace-
ment of the V3-loop of SIVagm in pRep10env by the
V3-loop of HIV-1 strain BH10 using standard PCR and
fusion-PCR techniques as described in Fig. 2. Primer
sequences are available upon request. Amino acid se-
quences of the V3-loops of HIV-1 strains BH10 (Wong-
Staal et al., 1985) and MBK (Cichutek et al., 1992) and of
wild-type SIVagm3mc are shown in Fig. 1B.
Cell lines
The human kidney cell line 293T (gift of M. Grez,
Georg-Speyer-Haus, Frankfurt, Germany), the human
rhabdomyosarcoma cell line TE671 (Stratton et al., 1989),
and the env-negative TE671-derived MLV packaging cell
line TELCeB6 (kindly provided by Y. Takeuchi and F.-L.
Cosset, Chester Beatty Laboratories, London, U.K.) (Cos-
set et al., 1995) as well as the TELCeB6-derived clone
K52SR20 (Stitz et al., 1998), were grown in Dulbecco’s
modified Eagle’s medium (DMEM; GIBCO/BRL, Eggen-
stein, Germany) supplemented with 10% heat-inactivated
FCS (Seromed, Biochrom KG, Berlin, Germany), 1% strep-
tomycin/penicillin, and 2 mM L-glutamine. All TELCeB6-
derived packaging cell clones were permanently cul-
tured in the presence of 5 g/ml blasticidine S (ICN) and
4.5 g/l glucose. The human osteosarcoma cell line
(HOS)-derived GHOST cell panel (provided by M. Dittmar,
Heinrich-Pette-Institut, Hamburg, Germany) expressing
one of various coreceptors in addition to human CD4 and
a tat-dependent GFP were cultivated as described (Ce-
cilia et al., 1998). The human T cell line Molt4/8 was
maintained in RPMI 1640 medium containing 10% FCS,
1% streptomycin/penicillin, and 2 mM L-glutamine.
Transient vector production
6  105 293T cells were seeded the day before trans-
fection in six-well culture plates (Nunc). Cells were trans-
fected with 1 g plasmid DNA of each expression con-
struct (pHIT60, pMFG-nlsLacZ, or pMgEGFP-LNGFR
and one of the Env variant encoding constructs) using
LipofectAMINE Plus according to manufacturer’s instruc-
tions (GIBCO/Life Technologies). One day after transfec-
tion, the medium was replaced by fresh medium. To
increase vector production, 10 mM sodium butyrate
(NaB) was added (Olsen and Sechelski, 1995). Vector-
containing supernatant was harvested 6 to 14 h after
medium exchange.
Generation of stable vector producer cell lines
To establish packaging cell lines continuously produc-
ing [MLV(SIVagm-wt)] and [MLV(SIVagm-X4)] vector par-
ticles, 5  105 TELCeB6 cells were transfected with 3 g
of plasmids pRep10env or pRep10env-X4, both coding
for a hygromycin B resistance gene in addition to the
SIVagm Env variant. Following hygromycin B selection
(200 g/ml; Boehringer Mannheim, Mannheim, Ger-
many), resistant cell colonies were tested for production
of vector particles able to transduce the respective
GHOST target cell line. Titrations with serial dilutions of
vector-containing supernatant were performed on
GHOST-CCR5 or GHOST-CXCR4 cells as described else-
where (Schnierle et al., 1997).
Similarly, the packaging cell line MBK15 which pro-
duces CCR5-tropic vector particles [MLV(HIV-R5)] was
established by transfection of TELCeB6 cells with the
CCR5-tropic HIV-1-env construct pTr712MBK and subse-
quent G418 selection (800 g/ml) and screening for vec-
tor production (I. Schmitt and K. Cichutek, unpublished
data).
Furthermore, a stable producer cell line for [MLV(MLV-
A)] vectors was generated by transfecting TELCeB6 cells
with the amphotropic MLV (4070A) Env encoding con-
struct pALF-MLV-A, harboring the resistance gene for
phleomycin. Bulk packaging cells were established by
selection in the presence of 50 g/ml phleomycin
(CAYLA, Toulouse, France). Vector titer was determined
on the GHOST-parental cell line as described elsewhere
(Schnierle et al., 1997).
Membrane fusion and in situ immunoperoxidase
assay
293T cells were transfected with plasmids encoding
the SIVagm env variants. On the following day, trans-
fected cells were overlaid with Molt4/8 T cells and cocul-
tivated for 2 days. Env-positive cells were detected by in
situ immunoperoxidase staining. Therefore, cells were
fixed by incubation with ice-cold methanol for 15 min.
After repeated washing with PBS, blocking buffer (2%
BSA in PBS) was added for 1 h at room temperature.
Cells were washed again and incubated at room tem-
perature with serum from an SIVagm3-infected pig-tailed
macaque (Macaca nemestrina) designated Nem170 in a
1:400 dilution. After further washing, cells were incu-
bated with peroxidase-conjugated protein-G (Bio-Rad,
Krefeld, Germany). Finally, antigen-expressing cells were
visualized by addition of substrate buffer (H2O2/3-amino-
9-ethylcarbazol, Sigma, Deisenhofen, Germany).
Vector harvest and determination of titers
Ninety percent confluent cultures of packaging cells
were incubated with little volume of cell culture medium
(10 ml per 182 cm2 flask) for 6 to 14 h. Supernatants were
filtrated (0.45 m), in some cases concentrated by ultra-
centrifugation (35,000 rpm in a Beckman SW41 rotor for
1.5 h at 4°C), resuspended in PBS, and stored at 80°C
until use.
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GHOST target cells were seeded in 12-well (1  105
cells per well) or 24-well (4  104 cells per well) culture
dishes. Five hundred microliters of serial dilutions of
vector-containing supernatants were added, incubated
for 3 h, and washed off. Two days posttransduction, cells
were analyzed for -Gal activity (Sanes et al., 1986).
Vector titers were calculated as described elsewhere
(Schnierle et al., 1997) and given as infectious units per
milliliters.
Inhibition of transduction in the presence of SDF-1
One day before transduction. 2  104 GHOST-CCR5
and GHOST-CXCR4 cells were seeded in 48-well culture
plates (Nunc). The cells were incubated with various
concentrations of SDF-1 (0.25–4 g/ml; R&D Systems,
Wiesbaden, Germany) 2 h prior to transduction. Added to
the SDF-1-containing media were 1  104 i.u. of [MLV-
(SIVagm-wt)] or [MLV(SIVagm-X4)] vector particles, re-
spectively. After a 3 h incubation period, the superna-
tants were removed and the cells were further cultivated
in the presence of SDF-1. Two days posttransduction,
cells were analyzed for -Gal activity (Sanes et al., 1986).
Western blot analysis of vector particles
Viral particles were pelleted from packaging cell su-
pernatants by ultracentrifugation through 20% sucrose
cushions in PBS at 35,000 rpm in a Beckman SW41 rotor
for 1.5 h at 4°C. Pellets were resuspended in PBS, sub-
jected to 10% SDS–PAGE, and transferred to a polyvi-
nylide fluoride (PVDF) membrane (Millipore, Eschborn,
Germany). Staining was performed using serum from an
SIVagm3-infected pig-tailed macaque (M. nemestrina)
designated Nem170, diluted 1:1000, and horseradish
peroxidase coupled protein G at a dilution of 1:1000,
using the enhanced chemiluminescence Western blot
detection kit (Amersham Pharmacia Biotech, Freiburg,
Germany). Detection of MLV gag proteins was performed
using a polyclonal anti-RLVp30gag serum in a 1:10,000
dilution (Viromed, NJ).
Neutralization assays
Sensitivity to neutralization by sera from HIV-1-infected
donors was tested by incubating 5  103 i.u. of vector
particles with 1:20 dilution of heat-inactivated sera from
HIV-1-infected donors or uninfected controls in a total
volume of 200 l for 1 h at 37°C. Samples were then
used to transduce 2  104 GHOST-CXCR4 cells in 48-
well dishes as described. Vector titers were estimated
after X-Gal staining of transduced cells.
Isolation and transduction of primary T-lymphocytes
Peripheral blood mononuclear cells (PBMC) were ob-
tained from healthy donors and isolated by centrifugation
on Ficoll–Histopaque (Sigma) and subsequent erythro-
cyte lysis in a 0.86% NH4Cl solution. Cells were adjusted
to a concentration of 1  106 cells per ml and stimulated
for 72 h with immobilized monoclonal antibodies, anti-
CD3, and anti-CD28 (Becton–Dickinson) in X-Vivo 10 me-
dium (BioWhittaker, Walkersville, MD) supplemented
with antibiotics, glutamine, 100 U/ml IL-2 (Chiron), 10%
FCS, and 10% autologous plasma. Autologous plasma
was obtained during purification of the PBMC and inac-
tivated for 1 h at 56°C before use.
After 3 days of stimulation, 24-well nontissue culture
plates (BD Falcon) precoated with the recombinant fi-
bronectin fragment RetroNectin (TaKaRa Biomedicals,
Otsu, Japan) (Fehse et al., 1998), 5  104 PBL suspended
in 250 l fresh medium, and 1 ml vector supernatant from
transiently transfected 293T was added, and the medium
was adjusted to a final concentration of 1 g/ml prota-
mine sulfate and 100 U/ml IL-2. The cell culture plates
were centrifuged for 90 min at 1000 rpm, 32°C in a
Varifuge 3.OR (Heraeus) centrifuge, and subsequently
incubated for 3 h at 37°C (Costello et al., 2000). Half of
the medium was exchanged by fresh medium. Three
cycles of transduction were performed on consecutive
days. Subsequently, the cells were kept for 3 days in
medium containing 100 U/ml IL-2.
Determination of gene transfer into PBL by FACS
analysis
Transduction efficiencies were assessed by flow cy-
tometry measuring EGFP and CD4 expression. Three
days after the last transduction, 2  105 PBL were
washed and resuspended in 30 l of 2% BSA, 0.01%
NaN3 in PBS and stained for 30 min with 5 l of anti-CD4
antibody (PerCP-conjugated, Becton–Dickinson) at 4°C.
Cells were washed twice with 500 l of 2% BSA, 0.01%
NaN3 in PBS. After fixation in 1% paraformaldehyde, the
cells were analyzed on a Galaxy flow cytometer (DAKO,
Copenhagen, Denmark).
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